SS Innovations International (NASDAQ: SSII) reported a 79% increase in cumulative procedures performed with its SSi Mantra surgical robotic system, reaching 14,103 as of Sept. 8, 2026, up from 7,885 at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units from 168, now spanning 12 countries. Approximately 1,500 physicians have been trained on the platform, which has been used for more than 170 types of surgical procedures.
These figures underscore the company's rapid commercial traction and its mission to make robotic surgery more affordable and accessible worldwide. The expansion into new markets and procedure types highlights the versatility of the SSi Mantra system, which supports cardiac surgery among other specialties.
Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. The company also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical for the company's expansion into high-value markets and could significantly accelerate adoption if achieved.
For more details, view the full report at https://ibn.fm/DJILj.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
